Most fat reduction injections come with a catch: swelling, pain, and days of hiding from the world. AMI Pharm thinks it’s time for something better.
Why This Matters
Submental fat—commonly called a “double chin”—is one of the most requested non-surgical treatments worldwide. The current FDA-approved option works by killing fat cells through necrosis.
That’s effective, but messy. It triggers inflammation, bruising, and a recovery period many patients want to avoid.
Meet AYP-101: Fat Reduction Without the Burn
AYP-101 is different. It uses apoptosis—programmed cell death—to target fat cells. No violent cell rupture. No big inflammatory response. The goal? Less pain, less swelling, and no downtime.
How It Works?
- Necrosis = inflammation, swelling, discomfort.
- Apoptosis = clean cell removal, minimal side effects.
By taking the gentler route, AYP-101 could change the patient experience from “hide for a week” to “back to work tomorrow.”
The Phase 3 Trial
- Participants: 252
- Location: Multi-site, South Korea
- Timeline: Completion expected end of 2025
- Why it’s big: Builds on strong Phase 1 and 2 data.
In Phase 2, over 70% of patients saw at least a one-grade improvement on the Evaluator-Reported Submental Fat Rating Scale.
Adverse events? Minimal.
Beyond the Chin
AMI Pharm isn’t stopping there.
The company is already mapping future uses for AYP-101, including:
- Cellulite reduction
- Deep buccal (cheek) fat removal
- Upper arm contouring
The Bigger Picture
CEO Ki-Taek Lee calls AYP-101 “the culmination of two decades of research.”
And the strategy is clear:
- Prove it works.
- Make it safer and more comfortable than the competition.
- Scale globally.
Global commercialization plans are already in motion. The drug is being showcased at leading industry events, from the BIO International Convention to the IMCAS World Congress.
Why Watch This
If Phase 3 delivers on the promise of early trials, AYP-101 could become the go-to non-surgical option for targeted fat reduction—fast, clean, and patient-friendly.
